The Duke Clinical Research Institute will become one of three national sites to run early clinical trials of new anti-infection therapies under a contract announced by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
The 10-year contract establishes DCRI in the Phase I Clinical Trial Units for Therapeutics, which NIAID began in 2008 to more quickly find promising therapies for diseases such as influenza, methicillin-resistant Staphylococcus aureus (MRSA) and drug-resistant tuberculosis.
DCRI could launch and manage up to four early-phase clinical trials a year, and potentially receive $90 million over the life of the contract, depending on the length and complexity of the different trials.
“DCRI is the only academic medical center to be awarded this contract,” says principal investigator Michael Cohen-Wolkowiez, MD, PhD, director of pharmacometrics and assistant director of the Duke Pediatric Clinical Research Unit at DCRI. “We bring an outstanding operations team and unique expertise, including a state-of-the-art clinical research unit, analytical support at our pharmacometrics center, and access to healthy volunteers and patients through the medical center.”
Cohen-Wolkowiez says the first clinical trials at Duke will likely start later this year, after infrastructure is established. The trials will be first-in-human studies, with the goal of identifying appropriate doses prior to continuing the drug development process.
“We look forward to participating in this important federal effort to speed development of new drugs and therapies for infectious diseases,” Cohen-Wolkowiez says. “As these diseases are increasingly resistant to current treatments, they pose a significant public health risk and highlight the urgent need for this work.”
Source: Duke University
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.